Evidence map›Paper›PMID 38040805›Full record

ArticleOncogene2024

Revealing the tumor suppressive sequence within KL1 domain of the hormone Klotho.

Marana Abboud, Keren Merenbakh-Lamin, Hadas Volkov, Shira Ben-Neriah, Hagai Ligumsky, Sarai Bronfeld, Noa Keren-Khadmy, Moshe Giladi, Noam Shomron, Ido Wolf and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Association ofInternational journal of molecular sciences · 2025
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Marana AbboudThe Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. abboudmarana@gmail.com.ORCID 0009-0004-9187-130X
Keren Merenbakh-LaminThe Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Hadas VolkovFaculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Shira Ben-NeriahThe Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Hagai LigumskyThe Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Sarai BronfeldThe Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Noa Keren-KhadmyThe Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Moshe GiladiFaculty of Medicine, Tel Aviv University, Tel Aviv, Israel.ORCID 0000-0002-8589-6920
Noam ShomronFaculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Ido WolfThe Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Tami RubinekThe Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. tamarru@tlvmc.gov.il.ORCID 0000-0003-4731-8887
Tel Aviv University · ILTel Aviv Sourasky Medical Center · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Klotho, a 1012 amino acid transmembrane protein, is a potent tumor suppressor in different cancer types. Klotho is composed of two internal repeats KL1 and KL2, and the tumor suppressor activity is primarily attributed to the KL1 domain. Despite its significant role in regulating various cancer-related pathways, the precise mechanism underlying its tumor suppressor activity remains unresolved. In this study, we aimed to identify the sequence responsible for the tumor suppressor function of Klotho and gain insights into its mechanism of action. To accomplish this, we generated expression vectors of truncated KL1 at the C and N-terminal regions and evaluated their ability to inhibit the colony formation of several cancer cell lines. Our findings demonstrated that truncated KL1 1-340 (KL340) effectively inhibited colony formation similar to KL1, while truncated KL1 1-320 (KL320) lost this activity. Furthermore, this correlated with the inhibitory effect of KL1 and KL340 on the Wnt/β-catenin pathway, whereas KL320 had no effect. Transcriptomic analysis of MCF-7 cells expressing the constructs revealed enriched pathways associated with tumor suppressor activity in KL1 and KL340. Interestingly, the α-fold predictor tool highlighted distinct differences in the α and β sheets of the TIM barrel fold of the truncated Klotho constructs, adding to our understanding of their structural variations. In summary, this study identified the 340 N-terminal amino acids as the sequence that possesses Klotho's tumor suppressor activity and reveals a critical role in the 320-340 sequence for this function. It also provides a foundation for the development of Klotho-based therapeutic approaches for cancer treatment.

Indexed as

Gene Expression ProfilingGlucuronidaseHormonesHumansMCF-7 CellsGlucuronidaseHormones

Identifiers

PMID38040805
OpenAlexW4389224641

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.